

Metallothionein 1 mediates growth and survival of *Dnmt3a*;*Npm1*-mutant acute myeloid leukemia

Authors

Patricia A. Colom Díaz,¹ Jayna J. Mistry,¹ Kira A. Young,¹ Chih-Hsing Chou,² Nathan Boyer,¹ Ross L. Levine,³ Nathan Salomonis,^{4,5} H. Leighton Grimes⁵ and Jennifer J. Trowbridge¹

¹The Jackson Laboratory, Bar Harbor, ME; ²Division of Immunobiology, Cincinnati Children's Hospital Medical Center (CCHMC), Cincinnati, OH; ³Memorial Sloan Kettering Cancer Center, New York, NY; ⁴Division of Biomedical Informatics, CCHMC, Cincinnati, OH and ⁵Division of Experimental Hematology and Cancer Biology, CCHMC, Cincinnati, OH, USA

Correspondence:

J.J. TROWBRIDGE – Jennifer.trowbridge@jax.org

<https://doi.org/10.3324/haematol.2025.287662>

Received: February 21, 2025.


Accepted: August 4, 2025.

Early view: August 14, 2025.


©2026 Ferrata Storti Foundation

Published under a CC BY-NC license





Supplementary Figure 1. Integrated comparison of bone marrow and spleen cells with *Dnmt3a;Npm1*-mutant AML progenitors. UMAP plots of cellHarmony-defined progenitor and mature cell types in (A) healthy bone marrow progenitors and splenocytes, (B) splenocytes only and (C) projected *Dnmt3a;Npm1*-mutant progenitors. (D) The proportion of progenitor and mature cell types within a c-Kit⁺ enriched fraction of 4 primary *Dnmt3a;Npm1*-mutant AML samples.



Supplementary Figure 2. Log2 fold change in *Mt1* expression in all cell types identified in c-Kit+ *Dnmt3a*;*Npm1*-mutant AML samples relative to the respective reference population. The vertical dotted line represents no change in expression.